Breaking News

Evotec Receives German Grant for Potential Therapy Against COVID-19

Under the grant, Evotec will initiate the clinical development of a potentially highly potent immunomodulatory molecule.

Author Image

By: Charlie Sternberg

Associate Editor

Evotec SE has been selected by the German Federal Ministry of Education and Research (BMBF) to receive a grant for the development of EVT075, a potential first-in-class immunomodulatory therapy against COVID-19. Evotec is one of three companies receiving a highly competitive grant as part of a new initiative by the BMBF to support the clinical development of novel therapeutic candidates against COVID-19. Under the €7.5 million ($8.5 million) grant, Evotec will use clinical material manufactur...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters